B lymphocyte signaling pathways in systemic autoimmunity: Implications for pathogenesis and treatment
- 9 September 2004
- journal article
- review article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 50 (9) , 2730-2741
- https://doi.org/10.1002/art.20487
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti‐CD154: A randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humansNature Genetics, 2002
- B cell–ablative therapy for the treatment of autoimmune diseasesArthritis & Rheumatism, 2002
- Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) acts as a regulator of B-cell development, B-cell antigen receptor (BCR)–mediated activation, and autoimmune diseaseBlood, 2002
- Abnormal T cell signal transduction in systemic lupus erythematosusArthritis & Rheumatism, 2002
- Fcγ receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: Contribution of FCGR2B to genetic susceptibilityArthritis & Rheumatism, 2002
- Protein kinase Cδ controls self-antigen-induced B-cell toleranceNature, 2002
- IgG Fc ReceptorsAnnual Review of Immunology, 2001
- Diminished levels of T cell receptor ? chains in peripheral blood T lymphocytes from patients with systemic lupus erythematosusArthritis & Rheumatism, 1999
- FcRECEPTOR BIOLOGYAnnual Review of Immunology, 1997